SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-20-000049
Filing Date
2020-08-06
Accepted
2020-08-06 16:13:09
Documents
16
Period of Report
2020-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-kearningsreleaseq22.htm   iXBRL 8-K 45245
2 EXHIBIT 99.1 ex991earningsreleaseq2.htm EX-99.1 92415
8 imagea15.jpg GRAPHIC 5087
  Complete submission text file 0000891293-20-000049.txt   293479

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20200630.xsd EX-101.SCH 4457
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20200630_cal.xml EX-101.CAL 628
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20200630_def.xml EX-101.DEF 1478
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20200630_lab.xml EX-101.LAB 26207
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20200630_pre.xml EX-101.PRE 13599
9 EXTRACTED XBRL INSTANCE DOCUMENT a8-kearningsreleaseq22_htm.xml XML 4306
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 201081770
SIC: 2834 Pharmaceutical Preparations